How much could $10,000 invested in CSL shares be worth next year?

Is CSL a good option for investors at current levels?

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

If you're lucky enough to have $10,000 available to invest, would it make sense to buy CSL Limited (ASX: CSL) shares?

Well, with the biotherapeutics giant widely regarded as one of Australia's highest-quality companies and its shares down 9% over the last 12 months, it certainly is an attractive proposition.

Let's dig deeper into things and see what that $10,000 could be worth in 12 months.

A doctor shrugs and holds his hands out.

Image source: Getty Images

$10,000 invested in CSL shares in 12 months

At present, CSL shares are changing hands for $267.10. This means that an investment of $10,000 would see you end up owning 37 units.

The good news is that brokers are overwhelmingly positive on the company and see plenty of upside for its shares over the next 12 months. This could potentially mean investors are getting a bit of a bargain at current prices.

For example, both Citi and UBS currently have buy ratings on the company's shares with a $340 price target.

If CSL shares were to rise to this level over the next 12 months, your 37 shares would be worth $12,580. That's a return of almost 26% or $2,580 on your original investment.

In addition, Citi is expecting CSL to pay dividends per share of $4.21 in FY 2024. This would add a further $155.77 of income to your return that could be reinvested or withdrawn.

All in all, if Citi is on the money with its recommendation, a $10,000 investment in CSL shares when the market reopens could lead to a total return of a touch under 27.5% or $2,750.

That's almost triple the average annual total return of 9.6% for ASX shares over the last 30 years.

Motley Fool contributor James Mickleboro has positions in CSL. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Blue Chip Shares

Happy man holding Australian dollar notes, representing dividends.
Blue Chip Shares

2 ASX blue-chip shares offering big dividend yields

These businesses can provide investors with good passive income.

Read more »

Person holding a blue chip.
Blue Chip Shares

2 ASX 200 blue-chip shares worth owning in April 2026

Is this a great time to invest in these shares?

Read more »

Young businesswoman sitting in kitchen and working on laptop.
Blue Chip Shares

Better buy? CSL vs Rio Tinto shares

When two quality shares diverge, I think it is worth taking a closer look.

Read more »

A man looking at his laptop and thinking.
Blue Chip Shares

These ASX blue chips now look too cheap to ignore

These blue chips could be worth a closer look after sharp declines.

Read more »

Young woman thinking with laptop open.
Blue Chip Shares

Why is everyone selling Wesfarmers shares?

It looks like the retail conglomerate fell out of favour with investors this year.

Read more »

Four business people wearing formal business suits and ties walk abreast on a wide paved surface with their long shadows falling on the ground ahead of them.
Blue Chip Shares

How did these ASX blue-chip shares perform in March?

Did these blue-chips beat the market in March?

Read more »

Couple looking at their phone surprised, symbolising a bargain buy.
Blue Chip Shares

Are these ASX blue chips now too cheap to ignore?

Let's see why these shares could be seriously undervalued at current levels.

Read more »

A woman gives two fist pumps with a big smile as she learns of her windfall, sitting at her desk.
Blue Chip Shares

3 reasons to buy Wesfarmers shares today

The retail conglomerate is a no-brainer buy in my book.

Read more »